RETRATO DE JOVEN CON COLGANTES [Material gráfico]

BARCELONA (ESPAÑA)Copia digital. Madrid : Ministerio de Educación, Cultura y Deporte, 201

Cultura Política de la Democracia en Costa Rica: 2006

El presente estudio sobre la cultura política democrática en Costa Rica en el año 2006 da seguimiento a un estudio similar realizado dos años atrás y forma parte de un esfuerzo más amplio de investigación comparada que, en esta ocasión, se realizó en diecisiete países de América Latina. La investigación procura no solo comparar la cultura política de los países, sino crear una herramienta útil para dar seguimiento a los cambios que éstas experimenten a lo largo del tiempo. La coordinación técnica de la investigación para toda la región estuvo a cargo de Mitchell Seligson, Profesor de la Universidad de Vanderbilt y creador del proyecto LAPOP. En Costa Rica, la investigación estuvo a cargo del Centro Centroamericano de Población de la Universidad de Costa Rica (CCP-UCR). En esta ocasión, el estudio de Costa Rica se basa en los resultados de una encuesta nacional sobre valores, actitudes y opiniones que se realizó en el mes de junio de 2006, mediante la cual se entrevistaron a 1.500 personas, con un tamaño y diseño similar al del estudio del 2004, lo que facilita las comparaciones entre ambos. Al igual que en la ronda 2004, el cuestionario aplicado tiene un tronco común, compartido con el conjunto de los países incluidos en el estudio, así como temas específicos desarrollados para el caso costarricense. El estudio del 2006 constata la existencia de importantes cambios en las actitudes ciudadana en una serie de factores relevantes de la vida política y social del país. De manera resumida estos cambios son los siguientes: se experimentó una baja simultánea en el apoyo al sistema, que fue acompañada por una disminución generalizada de la confianza en las principales instituciones públicas y actores sociales del país, mientras que, en el lapso de dos años, se registró un fuerte incremento en la sensación de inseguridad.UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias Sociales::Centro Centroamericano de Población (CCP

La Cultura Política de la Democracia en Costa Rica, 2004: Un estudio del Proyecto de Opinión Pública en América Latina (OPAL)

El presente estudio sobre la cultura política democrática en Costa Rica es parte de una investigación comparada que se realiza en ocho países de América Latina: México, Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panamá y Colombia. La investigación procura no solo comparar la cultura política de estos países sino crear una herramienta útil para dar seguimiento a los cambios que éstas experimenten a lo largo del tiempo. El estudio de Costa Rica se basa en los resultados de una encuesta nacional sobre valores, actitudes y opiniones que se realizó en el mes de marzo de 2004, mediante la cual se entrevistaron a 1.500 personas. Las personas estudiadas, que se seleccionaron con muestreo probabilístico, representan a la población nacional de 18 o más años de edad con derecho a voto. El cuestionario aplicado tiene un tronco común, compartido con el conjunto de los países incluidos en el estudio, así como temas específicos desarrollados para el caso costarricense. La coordinación técnica de la investigación para toda la región estuvo a cargo de Mitchell Seligson, Profesor de la Universidad de Vanderbilt y creador del proyecto OPAL. En Costa Rica, la investigación estuvo a cargo del Centro Centroamericano de Población de la Universidad de Costa Rica (CCP-UCR). El estudio confirma el amplio apoyo ciudadano a la democracia existente en Costa Rica. Por una parte, el apoyo a las instituciones del sistema político es el más alto de los ocho países estudiados en el estudio de OPAL -el puntaje promedio del país en una escala de 0-100 es 68. Este resultado supone una cierta recuperación del nivel de apoyo registrado cinco años atrás (61). Empero, desde una perspectiva de más largo plazo, no alcanza los niveles de veinte años atrás (85), por lo que puede hablarse de una tendencia al declive. El comparativo alto apoyo a las instituciones del sistema político es parte de una confianza genérica en las instituciones públicas del Estado costarricense, incluyendo tanto a las entidades de protección de derechos (Poder Judicial, Defensoría de los Habitantes, Contraloría General de la República) como a las entidades de prestación de servicios (CCSS, INS, ICE). (Solo los partidos políticos tienen un resultado francamente negativo, al igual que ocurre en los demás países). Por otra parte, dentro de los ocho países estudiados Costa Rica registra el mayor grupo de personas que apoyan al sistema político y, al mismo tiempo, tienen una alta tolerancia política hacia grupos minoritarios, lo que en el estudio se denomina apoyo a la democracia estable.UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias Sociales::Centro Centroamericano de Población (CCP

Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure

Clinical and cognitive progression in alpha-synucleinopathies is highly heterogeneous. While some patients remain stable over long periods of time, other suffer early dementia or fast motor deterioration. Sleep disturbances and nocturnal blood pressure abnormalities have been identified as independent risk factors for clinical progression but a mechanistic explanation linking both aspects is lacking. We hypothesize that impaired glymphatic system might play a key role on clinical progression. Glymphatic system clears brain waste during specific sleep stages, being blood pressure the motive force that propels the interstitial fluid through brain tissue to remove protein waste. Thus, the combination of severe sleep alterations, such as REM sleep behavioral disorder, and lack of the physiological nocturnal decrease of blood pressure due to severe dysautonomia may constitute the perfect storm for glymphatic failure, causing increased abnormal protein aggregation and spreading. In Lewy body disorders (Parkinson’s disease and dementia with Lewy bodies) the increment of intraneuronal alpha-synuclein and extracellular amyloid-β would lead to cognitive deterioration, while in multisystemic atrophy, increased pathology in oligodendroglia would relate to the faster and malignant motor progression. We present a research model that may help in developing studies aiming to elucidate the role of glymphatic function and associated factors mainly in alpha-synucleinopathies, but that could be relevant also for other protein accumulation-related neurodegenerative diseases. If the model is proven to be useful could open new lines for treatments targeting glymphatic function (for example through control of nocturnal blood pressure) with the objective to ameliorate cognitive and motor progression in alpha-synucleinopathies

An Introduction to the Study of Gastrotricha, with a Taxonomic Key to Families and Genera of the Group

Gastrotricha is a group of meiofaunal-sized, free-living invertebrates present in all aquatic ecosystems. The phylum includes over 860 species globally, of which 505 nominal species have been recorded in marine sandy sediments; another 355 taxa inhabit the freshwater environments, where they are recurrent members of the periphyton and epibenthos, and, to a lesser degree, of the plankton and interstitial fauna. Gastrotrichs are part of the permanent meiofauna and, in general, they rank among the top five groups for abundance within meiobenthic assemblages. The diversity, abundance, and ubiquity of Gastrotricha allow us to suppose an important role for these animals in aquatic ecosystems; however, ecological studies to prove this idea have been comparatively very few. This is mainly because the small size and transparency of their bodies make gastrotrichs dicult to discover in benthic samples; moreover, their contractility and fragility make their handling and morphological survey of the specimens rather dicult. Here we oer an overview, describe the basic techniques used to study these animals, and provide a key to known genera in an attempt to promote easy identification and to increase the number of researchers who may be interested in conducting studies on this understudied ecological group of microscopic organisms

ENVEJECIMIENTO Y SOLEDAD

Objective: The aim of this study is to analyze whether elderly people in a state of fragility, visited by the Emergency Domiciliary Care service, have received a follow-up program by the nursing staff and whether they were labeled as “Elderly people in state of fragility.” Material and method: A two-phase observational study. Firstly, in phase I, a population comprising people older than 64 and visited by the emergency domiciliary service from the Raval Nord Primary Care Centre was selected. Whether they had received nursing follow-up and whether they had been diagnosed as elderly people in a frail state was analyzed. In phase II, a simple random sample from this population was chosen. Here, it was analyzed whether there had been changes in the nursing diagnosis and follow-up. Results: Of a total was seen that of 776 medical emergency domiciliary visits, 568 (73.19%) were people belonging to the over 64 group. Out of the total, 57 cases (10%) belonged to the age group between 75 and 85 years old (80%). Out of this group, 77.26% were women; 94% were diagnosed with a chronic condition (diabetes, hypertension, chronic obstructive pulmonary disease, etc); and 77.2% were polymedicated. In addition, 66.7% were not included in the Domiciliary Care Program and were not diagnosed as frail elderly people. In phase II, an increase in nursing care, as well as in the “frail elderly people” diagnosis were found. Conclusions: The use of nursing diagnosis for elderly people in a frail state is an indispensable tool for the monitoring and follow-up of that population.Objetivo: Analizar si en las personas mayores en situación de fragilidad que han sido atendidas por el servicio de urgencias domiciliarias, constaba el seguimiento por el personal de enfermería del centro y  si constaba  el diagnóstico de “Personas mayores en situación de fragilidad”. Material y método: Se realizó un estudio observacional en dos fases: 1ª se analizaron todas las personas mayores de 64 años que fueron atendidas en el servicio de urgencias domiciliarias del centro de Atención Primaría de Raval Nord, se analizó si en dicha población constaba el seguimiento de enfermería y el diagnóstico de personas mayores en situación de fragilidad ; 2ª fase, se realizó un muestreo simple  de la población analizada y se evaluó si se produjeron cambios en  los diagnósticos de enfermería y seguimiento de dicha población. Resultados: De un total de 776 visitas domiciliarias de urgencias médicas, se observó que 568 (73,19%) eran mayores de 64 años. Del total, se estudiaron 57 (10%) casos y se observó que el 80% pertenecían al grupo de edad comprendido entre 75 y 85 años; el 77,26% eran mujeres; el 94% con diagnóstico crónico (Diabetes, Hipertensión Epoc...); el 77,2% eran personas polimedicadas y el 66,7% del total no estaban incluidas en el programa de Atención Domiciliaria y no constaba ningún diagnóstico de “personas mayores frágiles”. En la segunda fase se observa un incremento  en la atención por parte de los profesionales de enfermería y un aumento en el diagnóstico de “Personas mayores frágiles”. Conclusiones: La utilización del diagnóstico de enfermería en las personas en situación de fragilidad es una herramienta imprescindible para el seguimiento y control de dicha población.  

Diffusion Tensor Imaging Analysis Along the Perivascular Space in the UK Biobank

Background: The recently discovered glymphatic system may support the removal of neurotoxic proteins, mainly during sleep, that are associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s Disease. Diffusion tensor image analysis along the perivascular space (DTI-ALPS) has been suggested as a method to index the health of glymphatic system (with higher values indicating a more intact glymphatic system). Indeed, in small-scale studies the DTI-ALPS index has been shown to correlate with age, cognitive health, and sleep, and is higher in females than males. Objective: To determine whether these relationships are stable we replicated previous findings associating the DTI-ALPS index with demographic, sleep-related, and cognitive markers in a large sample of participants from the UK Biobank. Methods: We calculated the DTI-ALPS index in UK Biobank participants (n = 17723). Using Bayesian and Frequentist analysis approaches, we replicate previously reported relationships between the DTI-ALPS index. Results: We found the predicted associations between the DTI-ALPS index and age, longest uninterrupted sleep window (LUSWT) on a typical night, cognitive performance, and sex. However, these effects were substantially smaller than those found in previous studies. Parameter estimates from this study may be used as priors in subsequent studies using a Bayesian approach. These results suggest that the DTI-ALPS index is consistently, and therefore predictably, associated with demographics, LUWST, and cognition. Conclusion: We propose that the metric, calculated for the first time in a large-scale, population-based cohort, is a stable measure, but one for which stronger links to glymphatic system function are needed before it can be used to understand the relationships between glymphatic system function and health outcomes reported in the UKBiobank

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

Background A phase I study found remarkable activity and manageable toxicity for doxorubicin (bolus) plus lurbinectedin (1-h intravenous [i.v.] infusion) on Day 1 every three weeks (q3wk) as second-line therapy in relapsed small cell lung cancer (SCLC). An expansion cohort further evaluated this combination. Patients and methods Twenty-eight patients with relapsed SCLC after no more than one line of cytotoxic-containing chemotherapy were treated: 18 (64%) with sensitive disease (chemotherapy-free interval [CTFI] ≥90 days) and ten (36%) with resistant disease (CTFI <90 days; including six with refractory disease [CTFI ≤30 days]). Results Ten patients showed confirmed response (overall response rate [ORR] = 36%); median progression-free survival (PFS) = 3.3 months; median overall survival (OS) = 7.9 months. ORR was 50% in sensitive disease (median PFS = 5.7 months; median OS = 11.5 months) and 10% in resistant disease (median PFS = 1.3 months; median OS = 4.6 months). The main toxicity was transient and reversible myelosuppression. Treatment-related non-hematological events (fatigue, nausea, decreased appetite, vomiting, alopecia) were mostly mild or moderate. Conclusion Doxorubicin 40 mg/m(2) and lurbinectedin 2.0 mg/m(2) on Day 1 q3wk has shown noteworthy activity in relapsed SCLC and a manageable safety profile. The combination is being evaluated as second-line therapy for SCLC in an ongoing, randomized phase III trial. Clinical trial registration www.ClinicalTrials.gov code: NCT01970540. Date of registration: 22 October, 2013

Bisimilarity and refinement for hybrid(ised) logics

The complexity of modern software systems entails the need for reconfiguration mechanisms governing the dynamic evolution of their execution configurations in response to both external stimulus or internal performance measures. Formally, such systems may be represented by transition systems whose nodes correspond to the different configurations they may assume. Therefore, each node is endowed with, for example, an algebra, or a first-order structure, to precisely characterise the semantics of the services provided in the corresponding configuration. Hybrid logics, which add to the modal description of transition structures the ability to refer to specific states, offer a generic framework to approach the specification and design of this sort of systems. Therefore, the quest for suitable notions of equivalence and refinement between models of hybrid logic specifications becomes fundamental to any design discipline adopting this perspective. This paper contributes to this effort from a distinctive point of view: instead of focussing on a specific hybrid logic, the paper introduces notions of bisimilarity and refinement for hybridised logics, i.e. standard specification logics (e.g. propositional, equational, fuzzy, etc) to which modal and hybrid features were added in a systematic way.FC

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Background Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3middot2 mg/m2 every 3 weeks) received accelerated approval from the US Food and Drug Administration on the basis of efficacy in patients with small-cell lung cancer (SCLC) who relapsed after first-line platinum-based chemotherapy. The ATLANTIS trial assessed the efficacy and safety of combination lurbinectedin and the anthracycline doxorubicin as second-line treatment for SCLC.Methods In this phase 3, open-label, randomised study, adult patients aged 18 years or older with SCLC who relapsed after platinum-based chemotherapy were recruited from 135 hospitals across North America, South America, Europe, and the Middle East. Patients were randomly assigned (1:1) centrally by dynamic allocation to intravenous lurbinectedin 2middot0 mg/m2 plus doxorubicin 40middot0 mg/m2 administered on day 1 of 21-day cycles or physician's choice of control therapy (intravenous topotecan 1middot5 mg/m2 on days 1-5 of 21-day cycles; or intravenous cyclophosphamide 1000 mg/m2 , doxorubicin 45middot0 mg/m2 , and vincristine 2middot0 mg on day 1 of 21-day cycles [CAV]) administered until disease progression or unacceptable toxicity. Primary granulocyte-colony stimulating factor prophylaxis was mandatory in both treatment groups. Neither patients nor clinicians were masked to treatment allocation, but the independent review committee, which assessed outcomes, was masked to patients' treatment allocation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02566993, and with EudraCT, 2015-001641-89, and is complete.Findings Between Aug 30, 2016, and Aug 20, 2018, 613 patients were randomly assigned to lurbinectedin plus doxorubicin (n=307) or control (topotecan, n=127; CAV, n=179) and comprised the intention-to-treat population; safety endpoints were assessed in patients who had received any partial or complete study treatment infusions (lurbinectedin plus doxorubicin, n=303; control, n=289). After a median follow-up of 24middot1 months (95% CI 21middot7-26middot3), 303 patients in the lurbinectedin plus doxorubicin group and 289 patients in the control group had discontinued study treatment; progressive disease was the most common reason for discontinuation (213 [70%] patients in the lurbinectedin plus doxorubicin group vs 152 [53%] in the control group). Median overall survival was 8middot6 months (95% CI 7middot1-9middot4) in the lurbinectedin plus doxorubicin group versus 7middot6 months (6middot6-8middot2) in the control group (stratified log-rank p=0middot90; hazard ratio 0middot97 [95% CI 0middot82-1middot15], p=0middot70). 12 patients died because of treatment-related adverse events: two (<1%) of 303 in the lurbinectedin plus doxorubicin group and ten (3%) of 289 in the control group. 296 (98%) of 303 patients in the lurbinectedin plus doxorubicin group had treatment-emergent adverse events compared with 284 (98%) of 289 patients in the control group; treatment-related adverse events occurred in 268 (88%) patients in the lurbinectedin plus doxorubicin group and 266 (92%) patients in the control group.Grade 3 or worse haematological adverse events were less frequent in the lurbinectedin plus doxorubicin group than the control group (anaemia, 57 [19%] of 302 patients in the lurbinectedin plus doxorubicin group vs 110 [38%] of 288 in the control group; neutropenia, 112 [37%] vs 200 [69%]; thrombocytopenia, 42 [14%] vs 90 [31%]). The frequency of treatment-related adverse events leading to treatment discontinuation was lower in the lurbinectedin plus doxorubicin group than in the control group (26 [9%] of 303 patients in the lurbinectedin plus doxorubicin group vs 47 [16%] of 289 in the control group).Interpretation Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC. However, lurbinectedin plus doxorubicin showed a favourable haematological safety profile compared with control.Pathogenesis and treatment of chronic pulmonary disease